Clinical trials
Breast Cancer (Triple Negative Breast Cancer (TNBC)) clinical trials
Below are recruiting breast cancer (triple negative breast cancer (tnbc)) clinical trials, each written for real people, not researchers. We’re tracking 254 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06926868RecruitingPhase 2/Phase 3
Study of a new drug versus chemotherapy for advanced triple-negative breast cancer
This trial tests a new investigational drug called izalontamab brengitecan against standard chemotherapy for people with advanced triple-negative breast cancer who cannot receive immunotherapy. The goal is to see if the new drug works better at shrinking or slowing the cancer.
Hot Springs, ArkansasAges 18 years+ - NCT06908928RecruitingPhase 1
Study of Bulumtatug Fuvedotin for advanced triple-negative breast cancer
This study tests a new drug called bulumtatug fuvedotin for people with triple-negative breast cancer that has spread or come back. It's for those who have already tried certain other treatments, including a taxane and a specific type of antibody-drug conjugate.
Duarte, CaliforniaAges 18 years+ - NCT06910072Enrolling by invitationPhase 2/Phase 3
Chemo and immunotherapy before surgery for triple-negative breast cancer
This trial tests a combination of chemotherapy and two immunotherapy drugs given before surgery for women and men with triple-negative breast cancer. The goal is to see if this approach helps shrink or eliminate the tumor before surgery.
BeijingAges 18–75 - NCT06885424Enrolling by invitation
Long-term follow-up for A2 Bio gene therapy patients
This study follows up with people who previously received a gene therapy product from A2 Biotherapeutics in an earlier trial. The goal is to monitor their health over time and check for any long-term effects.
Gilbert, ArizonaAges 18 years+ - NCT06889688RecruitingPhase 3
New drug combo vs. chemo for advanced triple-negative breast cancer
This trial tests a new combination of three drugs (camrelizumab, apatinib, and eribulin) against the standard chemotherapy chosen by your doctor. It's for people with advanced triple-negative breast cancer that has gotten worse after previous treatments.
Guangzhou, GuangdongAges 18–70 - NCT06879704Recruiting
Predicting breast cancer response to pre-surgery therapy with X-rays
This trial uses special imaging before and after treatment to see if it can predict how well triple-negative breast cancer responds to chemotherapy plus immunotherapy given before surgery. Participation could help doctors tailor future treatments.
RouenAges 18–75 - NCT05396612Recruiting
Studying the immune response in non-cancer-spread breast surgery
This study looks at how your immune system changes while you receive standard breast cancer treatment around the time of surgery. The goal is to learn why some people respond better than others, which could help future treatment choices.
Philadelphia, PennsylvaniaAges 18 years+ - NCT05722795Recruiting
Imatinib to change triple-negative breast cancer to ER-positive
This trial studies whether imatinib (a pill medicine) can “convert” triple-negative breast cancer into an ER-positive type, which may change how the cancer behaves. If the conversion happens, it could open the door to more treatment options in the future.
GothenburgAges 18 years+ - NCT06841354RecruitingPhase 3
Sac-TMT alone or with pembrolizumab for advanced triple-negative breast cancer
This trial tests a new drug, Sac-TMT, given alone or with an immunotherapy drug (pembrolizumab) for people with advanced triple-negative breast cancer who have not yet received any treatment for advanced disease. The goal is to see if this combination can shrink tumors or slow the cancer's growth.
Mobile, AlabamaAges 18 years+ - NCT06845319RecruitingPhase 2
Chemo-immunotherapy before surgery for triple-negative breast cancer
This trial tests a new combination of chemotherapy and immunotherapy that avoids a class of drugs called anthracyclines, which can be hard on the heart. The goal is to shrink tumors before surgery for people with triple-negative or low-hormone-receptor breast cancer.
Charleston, South CarolinaAges 18 years+ - NCT06827613RecruitingPhase 1/Phase 2
Study of invikafusp alfa plus sacituzumab govitecan for advanced solid tumors
This trial tests a new drug combination for people with advanced breast cancer (triple-negative or hormone receptor-positive). The goal is to see if the combination helps shrink tumors or slow their growth.
Los Angeles, CaliforniaAges 18 years+ - NCT06831955RecruitingPhase 2
Lifestyle program to boost chemo before breast cancer surgery
This trial tests whether a structured lifestyle program (diet and exercise) can make standard chemotherapy before surgery work better for triple-negative breast cancer. It looks at how the program affects your body’s response to treatment and your overall health.
AntwerpAges 18 years+ - NCT06817525RecruitingPhase 2
Chemo and immunotherapy before surgery for early triple-negative breast cancer
This trial tests whether a combination of chemotherapy drugs (nab-paclitaxel and carboplatin) plus an immunotherapy drug (PD1 inhibitor) given before surgery can help treat early-stage triple-negative breast cancer. It aims to improve outcomes by using these treatments before the main surgery.
Zhengzhou, HenanAges 18–65 - NCT05862064RecruitingPhase 3
Adding an immune drug and anti-blood-vessel treatment to chemo
This study tests whether adding an immune therapy (a PD-1 antibody) plus a blood-vessel–blocking treatment to standard chemo improves outcomes for people with surgically treated triple-negative breast cancer. Everyone gets chemotherapy, but some will also get the added drugs to try to reduce cancer coming back.
Shanghai, Shanghai MunicipalityAges 18–70 - NCT06797635RecruitingPhase 2
Study of Patritumab Deruxtecan and Pembrolizumab for High-Risk Early Breast Cancer
This trial tests a combination of targeted therapies (patritumab deruxtecan plus pembrolizumab) along with other anticancer drugs for people with a high-risk type of early-stage breast cancer that is either triple-negative or has very low hormone receptors and is HER2-negative. The goal is to see if this approach can help prevent the cancer from coming back.
Santa Monica, CaliforniaAges 18 years+ - NCT06802757RecruitingPhase 2
Study of posaconazole with immunotherapy and chemo for triple-negative breast cancer
This trial tests if adding posaconazole (an antifungal drug) to standard immunotherapy and chemotherapy before breast cancer surgery works better than just the standard treatment. It is for people with newly diagnosed, early-stage triple-negative breast cancer.
Jinan, ShandongAges 18–70 - NCT06059469RecruitingPhase 2
PSMA scan for advanced triple-negative breast cancer
This trial uses a special scan (PSMA-PET/CT) to see if your breast cancer makes a protein called PSMA. The results might help guide your future treatment.
BrusselsAges 18 years+ - NCT06787339RecruitingPhase 2
Capecitabine for low-risk triple negative breast cancer
This trial tests whether a chemotherapy pill called capecitabine can help people with low-risk triple negative breast cancer after surgery. It is for patients with stage I disease who have certain features that suggest a lower chance of recurrence.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT05491083RecruitingPhase 1/Phase 2
Pembrolizumab plus ADG106 for advanced triple-negative breast cancer
This early-phase study tests pembrolizumab (an immune therapy) combined with ADG106 in people with advanced solid tumors, and specifically triple-negative breast cancer. It looks at whether the treatment can shrink tumors and improve outcomes for cancers that are progressing despite prior therapy.
SingaporeAges 21–99 - NCT06767527RecruitingPhase 3
AK112 plus chemo for first-line triple-negative breast cancer
This trial tests a new immunotherapy drug called AK112 combined with chemotherapy (nab-paclitaxel) for people with advanced triple-negative breast cancer who haven't had treatment yet. The goal is to see if AK112 works better than a placebo at shrinking tumors and helping people live longer.
BeijingAges 18–75 - NCT06768931RecruitingPhase 2
Combination therapy before surgery for triple-negative breast cancer
This trial tests adding an immunotherapy drug to standard chemotherapy before surgery for triple-negative breast cancer. The goal is to see if this combination works better than chemotherapy alone.
Lanzhou, GansuAges 18 years+ - NCT06744465Recruiting
Light-based monitoring for breast cancer during chemo
This study uses a special light-based device to monitor breast cancer during chemotherapy before surgery. It is for women with HER2-positive or triple-negative breast cancer who are planning chemotherapy first.
Indianapolis, IndianaAges 18 years+ - NCT06732323RecruitingPhase 3
Study of ESG401 for triple-negative breast cancer that has spread
This trial tests a new drug, ESG401, for people with triple-negative breast cancer that has come back or spread and cannot be removed by surgery. It compares ESG401 to standard chemotherapy options to see which works better.
BeijingAges 18 years+ - NCT06735131RecruitingPhase 2
Radiation and immunotherapy for advanced triple-negative breast cancer
This study tests a combination of radiation therapy and immunotherapy for people with advanced triple-negative breast cancer who haven't had chemotherapy for their advanced disease. It aims to see if adding radiation to standard chemotherapy can help shrink tumors and improve outcomes.
Guangzhou, GuangdongAges Any age
Hear when a new Breast Cancer (Triple Negative Breast Cancer (TNBC)) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for breast cancer (triple negative breast cancer (tnbc))?
- Yes. Clin2 currently lists 254 recruiting breast cancer (triple negative breast cancer (tnbc)) studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a breast cancer (triple negative breast cancer (tnbc)) trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a breast cancer (triple negative breast cancer (tnbc)) trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.